Sanjar Pharma Takes Bold Steps to Combat Malaria with Affordable, High-Quality Anti-Malarial Injections

Himatnagar, Gujarat - November 15, 2024 - In response to the staggering global burden of malaria, Sanjar Pharma LLP, a leading pharmaceutical manufacturer, has announced the availability of their affordable and high-quality anti-malarial injections to some of the most malaria-affected regions in Africa, including Nigeria, Zambia, Kenya, Uganda, Namibia, and South Africa.

Global Malaria Challenge

According to recent estimates, 249 million malaria cases were reported worldwide in 2022, with nearly 608,000 deaths across 85 countries. The WHO African Region bore the brunt of this crisis, accounting for 94% of all malaria cases and 95% of deaths. Vulnerable groups such as children under five years of age represented 78% of all malaria-related deaths, and 12.7 million pregnant women suffered from malaria infections, posing grave risks to maternal and infant health.
Nigeria alone accounted for 26.8% of global malaria cases and 31% of deaths, while the Democratic Republic of the Congo, Uganda, and Mozambique made up nearly half of all global cases.

Sanjar Pharma's Commitment to Fighting Malaria

In light of this urgent public health crisis, Sanjar Pharma has reinforced its commitment to improving access to effective anti-malarial treatments. Their specialized anti-malarial injections-Arteether, Artemether, and Quinine Dihydrochloride-are designed to combat severe malaria cases caused by Plasmodium falciparum, a parasite responsible for life-threatening infections.

Our goal is to provide direct access to high-quality, life-saving medications that address the unique challenges faced by heavily affected regions," said a spokesperson for Sanjar Pharma.

"By offering cost-effective solutions and eliminating intermediaries, we ensure faster delivery and reliable supply chains for clinics and hospitals.

Comprehensive Solutions to Combat Malaria

Sanjar Pharma's anti-malarial portfolio is tailored to meet the needs of countries facing the highest malaria burdens:
Arteether Injections: Administered intramuscularly, they are highly effective in treating severe malaria and are ideal for patients unable to take oral medications due to complications such as vomiting.

Artemether Injections: Known for their rapid action, these injections kill parasites within 48 hours, preventing complications like cerebral malaria, organ failure, and severe anemia.

Quinine Dihydrochloride Injections: A critical solution for blood-stage malaria, these injections target high parasite loads that can lead to cerebral complications and severe anemia, especially in emergency scenarios.

Direct Access for African Regions

Sanjar Pharma is now enabling bulk orders of anti-malarial injections directly from their facilities, bypassing third parties to streamline procurement for healthcare providers in malaria-affected countries. With a minimum bulk order starting at $200, this initiative ensures affordability, simplified logistics, and timely delivery of life-saving medications.

A Trusted Partner in Global Health

Founded in 2014 and headquartered in Himatnagar, Gujarat, Sanjar Pharma has become a trusted name in pharmaceutical manufacturing, specializing in injections, including dry powder injections, liquid vials, ampoule injections, and more. Their dedication to quality and affordability has made them a vital partner for healthcare providers worldwide.
For inquiries or to place bulk orders for anti-malarial injections, please contact Sanjar Pharma:
Email: marketing@sanjarpharma.com
WhatsApp: +91 6352986603
Call: +91 2772-245249
Together, let's combat malaria and save lives.

Himatnagar - Vijapur Hwy, Dedhrota, Gujarat

Sanjar Pharma is a fast-growing pharmaceutical company dedicated to improving global health through high-quality, affordable medications. With a strong presence in international markets and a diverse portfolio of pharmaceutical solutions, Sanjar Pharma remains committed to addressing some of the world's most pressing healthcare challenges.

This release was published on openPR.